Kira Biotech
Brunswick
About Kira Biotech
Kira Biotech is an emerging Australian biotechnology company developing novel immunomodulatory compounds for the treatment of immune system disorders. Its lead candidate, KB312, is a first-in-class, selective, immune-cell depleting monoclonal antibody which targets activated immune cells and aims to restore homeostasis through induction of immune tolerance. Kira Biotech has attracted venture capital funding and is progressing KB312 through preclinical development and phase 1 clinical trials with a team of drug development experts led by well-known US-based rheumatologist and immunologist, Dr Dan Baker.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $13.7M
- Funding stage: Early Stage Venture
- Last round: Series A (Oct 2019)
- Website: kirabiotech.com
- Phone: [email protected]
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/kira-biotech-11479 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.